OR WAIT null SECS
© 2023 MJH Life Sciences and Formulary Watch. All rights reserved.
© 2023 MJH Life Sciences™ and Formulary Watch. All rights reserved.
August 03, 2022
Coherus’ Cimerli has been approved to be interchangeable for all five indications, including age-related macular degeneration and diabetic retinopathy. It will be available in early October 2022.
July 20, 2022
Pegcetacoplan is a targeted therapy to treat patients with age-related macular degeneration. The Prescription Drug User Fee Act (PDUFA) target action date is Nov. 26, 2022.
July 07, 2022
NOV03 (perfluorohexyloctane) is a first-in-class eye drop with a novel mechanism of action. If approved it will be the first to address signs and symptoms of dry eye disease.
June 29, 2022
Regeneron is seeking an additional dosing regimen with a longer-term interval between doses. The PDUFA date is Feb. 28, 2023.
June 21, 2022
Xipere became commercially available in March 2022. It is the first therapy for patients with macular edema that provides a targeted delivery to the retina.
June 02, 2022
Byooviz, the first FDA approved ophthalmology biosimilar for macular degeneration, will be priced 40% lower than the reference product. It will be commercially available on July 1, 2022.
April 25, 2022
Phase 3 trials show CSF-1, a low-dose pilocarpine, met clinical endpoints for improving presbyopia, or age-related blurry vision.
March 28, 2022
Xipere is a targeted treatment that is delivered via an injection to the back of the eye to treat macular edema associated with uveitis, a form of eye inflammation.
March 23, 2022
Cystaran is a topical ophthalmic therapy that is used to treat a rare genetic disorder.
March 11, 2022
This expands commercial coverage to 118 million lives and Medicare coverage to 7.1 million lives.